Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | TPH1 | P17752 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839117 | 1.00 | MMP8 (0.44) | MMP8TPH1MAPK1MEN1S1PR4 | |
| SCHEMBL839784 | 1.00 | MMP8 (0.44) | MMP8TPH1MAPK1MEN1S1PR4 | |
| Hydrochloric Acid SCHEMBL27136330 | 0.98 | TPH1 (0.45) | MMP8TPH1MAPK1MEN1S1PR4 | |
| Hydrochloric Acid SCHEMBL1681290 | 0.98 | TPH1 (0.45) | MMP8TPH1MAPK1MEN1S1PR4 | |
| SCHEMBL7960935 | 0.91 | SLC7A5 (0.48) | MMP8TPH1SLC7A5ALPIPKM | |
| SCHEMBL9967935 | 0.86 | SLC7A5 (0.44) | MMP8TPH1MEN1LMNAMAPT | |
| SCHEMBL20543461 | 0.86 | SLC7A5 (0.44) | MMP8TPH1MEN1LMNAMAPT | |
| SCHEMBL21117856 | 0.86 | SLC7A5 (0.44) | MMP8TPH1MEN1LMNAMAPT | |
| SCHEMBL14139328 | 0.86 | SLC7A5 (0.44) | MMP8TPH1MAPK1LMNAACACB | |
| SCHEMBL2369810 | 0.85 | HDAC1 (0.51) | MEN1MAPTKMT2AACACBSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954840-A | Preparation method of 4-boric acid-L-phenylalanine | 北京晶强科技中心(有限合伙) | 2025-05-09 | — | — | CN | claimed |
| CN-119954840-A | Preparation method of 4-boric acid-L-phenylalanine | 北京晶强科技中心(有限合伙) | 2025-05-09 | — | — | CN | disclosed |
| EP-3015488-B1 | PRODUCTION METHOD FOR POLYAMINO ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2020224652-A1 | UBIQUITIN-SPECIFIC PROTEASE INHIBITORS, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京普济远成生物科技有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-10336864-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9815938-B2 | Production method for poly(amino acid) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-23 | — | — | US | disclosed |
| EP-3015488-A1 | PRODUCTION METHOD FOR POLYAMINO ACID | Takeda Pharmaceutical Company Limited (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| EP-1307455-A2 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| WO-2001030781-A2 | INHIBITORS OF αLβ2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| US-4857553-A | SIDE EFFECT REDUCTION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-08-15 | — | — | US | disclosed |
| EP-0302757-A2 | Anti-emetic serotonin depleting agents | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4749728-A | HAVING HYDROXY-FUNCTIONAL AND CARBOXYLIC ESTER-FUNCTIONAL RESINS OR COMPONENTS | THE GLIDDEN COMPANY (US) | 1988-06-07 | — | — | US | disclosed |
| EP-0252289-A2 | Transesterification catalysts and thermoset coatings | THE GLIDDEN COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044472-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | MMP8 4693/4885TPH1 3735/4885MAPK1 664/4885 |
| US-10336864-B2 | Production method for poly(amino acid) | PGA5, ENPEP, PARG | MMP8 4693/4885TPH1 3735/4885MAPK1 664/4885 |
| US-20160177032-A1 | PRODUCTION METHOD FOR POLY(AMINO ACID) | PGA5, ENPEP, PARG | MMP8 4693/4885TPH1 3735/4885MAPK1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.